Piper Sandler adds Stuart M. Essig to board, expanding it to ten directors
Piper Sandler Companies elected Stuart M. Essig as a director effective February 4, 2026, increasing the board from nine to ten members. He was also appointed to the Audit Committee, and the filing describes his prior roles as chief executive and chairman of Integra LifeSciences Corporation.
Key points
- Essig's initial term expires at the 2026 annual shareholder meeting.
- Essig joins the Audit Committee of the Board.
- Under the 2026 non-employee director program, he receives a pro-rated $100,000 annual cash retainer, a $60,000 initial equity grant, and a $150,000 annual equity grant after the 2026 annual meeting.
- The filing states Essig has no related person transactions with the Company.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:00 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.